Clinical Trials Using Mogamulizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Mogamulizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Mogamulizumab and Pembrolizumab in Treating Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    This phase I / II trial studies the best dose and side effects of mogamulizumab in combination with pembrolizumab and to see how well they work in treating patients with diffuse large B cell lymphoma that have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as mogamulizumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 8 locations

  • KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

    The purpose of this study is to characterize the safety, tolerability, and determine the maximum tolerated dose (MTD) or the highest protocol-defined dose, in the absence of exceeding the MTD, of KHK2455 administered orally in combination with mogamulizumab to subjects with locally advanced or metastatic solid tumors.
    Location: 3 locations

  • Mogamulizumab in Treating Patients with Solid Tumors That Cannot Be Removed by Surgery

    This phase I / II trial studies the safety and best dose of mogamulizumab and to see how well it works in treating patients with solid tumors that cannot be removed by surgery. Monoclonal antibodies, such as mogamulizumab, may block tumor growth in different ways by targeting certain cells that express C-C chemokine receptor 4 (CCR4).
    Location: Memorial Sloan Kettering Cancer Center, New York, New York